Katherine R Tuttle1, Lance D Dworkin2, William Henrich3, Barbara A Greco4, Michael Steffes5, Sheldon Tobe6, Joseph I Shapiro7, Kenneth Jamerson8, Asya Lyass9, Karol Pencina9, Joseph M Massaro9, Ralph B D'Agostino9, Donald E Cutlip10, Timothy P Murphy2, Christopher J Cooper11. 1. Providence Health Care, University of Washington, Spokane, Washington; katherine.tuttle@providence.org. 2. Brown University, Providence, Rhode Island; Rhode Island Hospital, Providence, Rhode Island; 3. University of Texas Health Science Center, San Antonio, Texas; 4. Baystate Health, Springfield, Massachusetts; 5. University of Minnesota, Minneapolis, Minnesota; 6. University of Toronto, Toronto, Ontario, Canada; 7. Marshall University, Huntington, West Virginia; 8. University of Michigan, Ann Arbor, Michigan; 9. Harvard Clinical Research Institute, Boston University, Boston, Massachusetts; 10. Beth Israel Deaconess Medical Center, Boston, Massachusetts; and. 11. University of Toledo, Toledo, Ohio.
Abstract
BACKGROUND AND OBJECTIVES: Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (from May of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage ≥3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (≥30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. RESULTS: eGFR was 59±24 ml/min per 1.73 m(2) (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was -1.5±7.0 ml/min per 1.73 m(2) per year in the stent group versus -2.3±6.3 ml/min per 1.73 m(2) per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, and HDL cholesterol (positive associations). CKD outcomes events occurred in 19% (175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). CONCLUSIONS:Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.
RCT Entities:
BACKGROUND AND OBJECTIVES:Atherosclerotic renal artery stenosis may cause kidney function loss, but effects of stenting on eGFR and clinical events associated with CKD are uncertain. Our study objectives were to determine effects of stenting on eGFR and predictors of clinical events. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Participants (n=931) in the Cardiovascular Outcomes in Renal Artery Stenosis Trial (from May of 2005 to September of 2012) had >60% atherosclerotic renal artery stenosis and systolic hypertension on two or more antihypertensive drugs and/or stage ≥3 CKD. The intervention was stenting versus no stenting on a background of risk factor management: renin-angiotensin system inhibition, statin, antiplatelet therapy, and smoking cessation education. The effect of stenting on eGFR by the serum creatinine-cystatin C Chronic Kidney Disease Epidemiology Collaboration equation was the prespecified analysis of kidney function. Predictors of eGFR and CKD outcomes (≥30% eGFR loss, ESRD, and death) and cardiovascular disease outcomes (stroke, myocardial infarction, heart failure, and death) controlling for eGFR and albuminuria were also determined. RESULTS:eGFR was 59±24 ml/min per 1.73 m(2) (mean±SD) at baseline. Over 3 years, eGFR change, assessed by generalized estimating equations, was -1.5±7.0 ml/min per 1.73 m(2) per year in the stent group versus -2.3±6.3 ml/min per 1.73 m(2) per year in the medical therapy only group (P=0.18). eGFR predictors (multiple variable generalized estimating equations) were age, albuminuria, systolic BP, and diabetes (inverse associations) as well as men, total cholesterol, and HDL cholesterol (positive associations). CKD outcomes events occurred in 19% (175 of 931), and predictors (Cox proportional hazards models) included albuminuria (positive association), systolic BP (positive association), and HDL cholesterol (inverse association). Cardiovascular disease outcomes events occurred in 22% (207 of 931), and predictors included age, albuminuria, total cholesterol, prior cardiovascular disease, and bilateral atherosclerotic renal artery stenosis (positive associations). CONCLUSIONS: Stenting did not influence eGFR in participants with atherosclerotic renal artery stenosis receiving renin-angiotensin system inhibition-based therapy. Predictors of clinical events were traditional risk factors for CKD and cardiovascular disease.
Authors: U Blum; B Krumme; P Flügel; A Gabelmann; T Lehnert; C Buitrago-Tellez; P Schollmeyer; M Langer Journal: N Engl J Med Date: 1997-02-13 Impact factor: 91.245
Authors: M Rodriguez-Porcel; J D Krier; A Lerman; P F Sheedy; J C Romero; C Napoli; L O Lerman Journal: Hypertension Date: 2001-02 Impact factor: 10.190
Authors: M W Burket; C J Cooper; D J Kennedy; P S Brewster; G M Ansel; J A Moore; J Venkatesan; W L Henrich Journal: Am Heart J Date: 2000-01 Impact factor: 4.749
Authors: James Ritchie; Darren Green; Constantina Chrysochou; Nicholas Chalmers; Robert N Foley; Philip A Kalra Journal: Am J Kidney Dis Date: 2013-09-26 Impact factor: 8.860
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: Liesbeth Bax; Arend-Jan J Woittiez; Hans J Kouwenberg; Willem P T M Mali; Erik Buskens; Frederik J A Beek; Branko Braam; Frans T M Huysmans; Leo J Schultze Kool; Matthieu J C M Rutten; Cornelius J Doorenbos; Johannes C N M Aarts; Ton J Rabelink; Pierre-François Plouin; Alain Raynaud; Gert A van Montfrans; Jim A Reekers; Anton H van den Meiracker; Peter M T Pattynama; Peter J G van de Ven; Dammis Vroegindeweij; Abraham A Kroon; Michiel W de Haan; Cornelis T Postma; Jaap J Beutler Journal: Ann Intern Med Date: 2009-05-04 Impact factor: 25.391
Authors: Mohsen Afarideh; Xin Zhang; Christopher M Ferguson; James F Glockner; Amir Lerman; Stephen C Textor; Lilach O Lerman Journal: Hypertension Date: 2020-06-08 Impact factor: 10.190
Authors: Holly J Kramer; Raymond R Townsend; Karen Griffin; Joseph T Flynn; Daniel E Weiner; Michael V Rocco; Michael J Choi; Matthew R Weir; Tara I Chang; Rajiv Agarwal; Srinivasan Beddhu Journal: Am J Kidney Dis Date: 2019-04 Impact factor: 8.860
Authors: Amy E Burchell; Jonathan C L Rodrigues; Max Charalambos; Laura E K Ratcliffe; Emma C Hart; Julian F R Paton; Andreas Baumbach; Nathan E Manghat; Angus K Nightingale Journal: J Clin Hypertens (Greenwich) Date: 2016-10-19 Impact factor: 3.738
Authors: Clemens Grupp; Michael J Koziolek; Manuel Wallbach; Kerstin Hoxhold; Gerhard A Müller; Carsten Bramlage Journal: J Clin Hypertens (Greenwich) Date: 2018-02-16 Impact factor: 3.738